Endophthalmitis

Jump to navigation Jump to search

WikiDoc Resources for Endophthalmitis

Articles

Most recent articles on Endophthalmitis

Most cited articles on Endophthalmitis

Review articles on Endophthalmitis

Articles on Endophthalmitis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Endophthalmitis

Images of Endophthalmitis

Photos of Endophthalmitis

Podcasts & MP3s on Endophthalmitis

Videos on Endophthalmitis

Evidence Based Medicine

Cochrane Collaboration on Endophthalmitis

Bandolier on Endophthalmitis

TRIP on Endophthalmitis

Clinical Trials

Ongoing Trials on Endophthalmitis at Clinical Trials.gov

Trial results on Endophthalmitis

Clinical Trials on Endophthalmitis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Endophthalmitis

NICE Guidance on Endophthalmitis

NHS PRODIGY Guidance

FDA on Endophthalmitis

CDC on Endophthalmitis

Books

Books on Endophthalmitis

News

Endophthalmitis in the news

Be alerted to news on Endophthalmitis

News trends on Endophthalmitis

Commentary

Blogs on Endophthalmitis

Definitions

Definitions of Endophthalmitis

Patient Resources / Community

Patient resources on Endophthalmitis

Discussion groups on Endophthalmitis

Patient Handouts on Endophthalmitis

Directions to Hospitals Treating Endophthalmitis

Risk calculators and risk factors for Endophthalmitis

Healthcare Provider Resources

Symptoms of Endophthalmitis

Causes & Risk Factors for Endophthalmitis

Diagnostic studies for Endophthalmitis

Treatment of Endophthalmitis

Continuing Medical Education (CME)

CME Programs on Endophthalmitis

International

Endophthalmitis en Espanol

Endophthalmitis en Francais

Business

Endophthalmitis in the Marketplace

Patents on Endophthalmitis

Experimental / Informatics

List of terms related to Endophthalmitis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]

Enophthalmitis may be classified according to causative organisms into 2 subtypes: Bacterial and fungal.

Additionally, endophthalmitis is classified as either endogenous or exogenous based on the route of infection.

Overview

Endophthalmitis is an inflammation of the internal coats of the eye. It is a dreaded complication of all intraocular surgeries, particularly cataract surgery, with possible loss of vision and the eye itself. Infectious etiology is the most common and various bacteria and fungi have been isolated as the cause of the endophthalmitis. Other causes include penetrating trauma and retained intraocular foreign bodies.

Pathophysiology

Pathogenesis

Endophthalmitis is an ocular inflammation resulting from the introduction of an infectious agent, either bacterial or fungal, into the posterior segment of the eye. Infectious agents are introduce to the anterior and posterior segments of the eye exogenously or endogenously.[1][2]

Exogenous enophthalmitis most commonly occurs following cataract surgery (approximately 90% of all cases) Beside cataract, nearly all other type of ocular surgery, such as glaucoma, retinal, radial keratotomy, and intravitreal injections, may be able to disturb the eye globe integrity and contaminate the aqueous humor and/or vitreous.[1][2][3] Most commonly endophthalmitis occurs following penetrating ocular injuries. Following penetrating injury, the eye globe integrity disturbed. Penetrating ocular injuries are accompanied by infection at a much higher rate compere to those with ocular surgery. It is also associated with a greater variety of organisms. The most common isolated organisms include Gram-positive Staphylococcus epidermidis and Streptococcus.[2][4]

Endogenous endophthalmitis is caused by the hematologic dissemination of an infection to the eyes. Most common extraocular foci of infection include liver abscess, pneumonia, endocarditis, and soft tissue infection. Endogenous endophthalmitis is commonly associated with immunosuppression or procedures that increase the risk for blood-borne infections, such as diabetes, HIV, malignancy, intravenous drug use, transplantation, immunosuppressive therapy, and catheterization.[1][2][5]

Gross Pathology

On gross pathology, eyelid swelling, eyelid erythema, injected conjunctiva and sclera, hypopyon, chemosis, and mucoprulunt dischage are characteristic findings of exogenous bacterial endophthalmitis.

Microscopic histopathological analysis

On microscopic histopathological analysis, infiltration of polymorphonuclear leukocytes or chronic inflammatory cells (depending on the duration of the inflammation) and destruction of ocular structures are characteristic findings of bacterial endophthalmitis.

Causes

Drug side-effect

Infectious

Common bacterial and fungal causes of endophthalmitis include:

Epidemiology and Demographics

  • In the United States, post-cataract endophthalmitis is the most common form of endophthalmitis.
  • The incidence of post-cataract endophthalmitis was estimated to range from 80 to 360 cases per 100,00 individuals with ocular surgery.[6]

Risk Factors

Endogenous bacterial endophthalmitis

Common risk factors in the development of endogenous bacterial endophthalmitis include:[1][2][5]

Signs and symptoms

A history of recent intraocular surgery or penetrating ocular trauma is usually elicited. In some cases of metastatic endophthalmitis, the spread of infection may be hematogenous (via the blood-stream). That is more commonly seen in patients with immunocompromised states like AIDS and also in diabetes. The condition is usually accompanied by severe pain, loss of vision and redness of the conjunctiva and the underlying episclera. Alongside are present signs of inflammation of the various coats of the eye. Hypopyon can also be present in endophthalmitis and should be looked for on examination by a slit lamp. Progression to involve all the coats of the eye is called as panuveitis or panophthalmitis.

Slit lamp finding

Treatment

  • The patient needs urgent examination by an expert ophthalmologist and/or vitreo-retina specialist who will usually decide for urgent intervention to provide intravitreal injection of potent antibiotics and also prepare for an urgent pars plana vitrectomy as needed. Enucleation may be required to remove a blind and painful eye.
  • Endogenous endophthalmitis is caused by the hematologic dissemination of an infection to the eyes. Systemic antibiotics are recommended in endogenous bacterial endophthalmitis because the source of the infection is distant from the eye.
  • Bacterial and fungal cultures from vitreous samples are necessary in the management of endophthalmitis
  • Immediate vitrectomy is often necessary

Antimicrobial Regimens

  • Infectious endophthalmitis[1]
  • 1. Causative pathogens
  • 2. Empiric antimicrobial therapy
  • Preferred regimen: Vancomycin 1 mg per 0.1 mL normal saline intravitreal injection, single dose AND Vancomycin 1 g IV bid for 2 weeks AND Ceftazidime 2.25 mg per 0.1 mL normal saline intravitreal injection, single dose AND Ceftazidime 1 g IV bid for 2 weeks AND Clindamycin 600-1200 mg IV bid to qid for 2 weeks
  • Note (1): Re-injection should be considered if the infection does not improve beyond 48 hours of the first injection. Re-injection significantly increases the risk of retinal toxicity.
  • Note (2): In addition to intravitreal and systemic antibiotic therapy, vitrectomy is usually necessary
  • Note (3): Intravitreal and intravenous Amphotericin B may be added to the regimen if fungal endophthalmitis is suspected
  • 3. Pathogen-directed antimicrobial therapy
  • 3.1 Bacillus spp.
  • Preferred regimen: Vancomycin 1 mg per 0.1 mL normal saline intravitreal injection, single dose AND Vancomycin 1 g IV bid for 2 weeks AND Clindamycin 600-1200 mg IV bid to qid for 2 weeks
  • Note: In addition to antimicrobial therapy, vitrectomy is usually necessary
  • 3.2 Non-Bacillus gram-positive bacteria
  • Preferred regimen: Vancomycin 1 mg per 0.1 mL normal saline intravitreal injection, single dose AND Vancomycin 1 g IV bid for 2 weeks
  • Note: In addition to antimicrobial therapy, vitrectomy is usually necessary
  • 3.3 Gram-negative bacteria
  • Preferred regimen: Ceftazidime 2.25 mg per 0.1 mL normal saline intravitreal injection, single dose AND Ceftazidime 1 g IV bid for 2 weeks
  • Note: In addition to antimicrobial therapy, vitrectomy is usually necessary
  • 3.4 Candida spp.
  • Preferred regimen: (Fluconazole 400-800 mg IV/PO qd for 6-12 weeks OR Voriconazole 400 mg IV/PO bid for 2 doses followed by 200-300 mg IV/PO bid for 6-12 weeks OR Amphotericin B 0.7-1.0 mg/kg IV qd for 6-12 weeks) AND Amphotericin B 5-10 microgram in 0.1 mL in normal saline intravitreal injection, single dose
  • Note (1): In addition to antimicrobial therapy, vitrectomy is usually necessary
  • 3.5 Aspergillus spp.
  • Preferred regimen: Amphotericin B 5-10 microgram in 0.1 mL normal saline intravitreal injection, single dose AND Dexamethasone 400 microgram intravitreal injection, single dose
  • Note (1): In addition to antimicrobial therapy, vitrectomy is usually necessary
  • Note (2): Repeat antimicrobial regimen in 2 days post-vitrectomy
  • 4. Special Considerations
  • 4.1 Endogenous endophthalmitis
  • 4.1.1 Empiric antimicrobial therapy
  • Preferred regimen: Vancomycin 1 mg per 0.1 mL normal saline intravitreal injection, single dose AND Vancomycin 1 g IV bid for 2 weeks AND Ceftazidime 2.25 mg per 0.1 mL normal saline intravitreal injection, single dose AND Ceftazidime 1 g IV bid for 2 weeks AND Clindamycin 600-1200 mg IV bid to qid for 2 weeks
  • Note (1): Re-injection should be considered if the infection does not improve beyond 48 hours of the first injection. Re-injection significantly increases the risk of retinal toxicity.
  • Note (2): In addition to intravitreal and systemic antibiotic therapy, vitrectomy is usually necessary::* Note (3): Intravitreal and intravenous Amphotericin B may be added to the regimen if fungal endophthalmitis is suspected
  • 4.2 Bleb-related endophthalmitis
  • 4.2.1 Empiric antimicrobial therapy
  • Preferred regimen: Vancomycin 1 mg per 0.1 mL normal saline intravitreal injection, single dose AND Vancomycin 1 g IV bid for 2 weeks AND Ceftazidime 2.25 mg per 0.1 mL normal saline intravitreal injection, single dose AND Ceftazidime 1 g IV bid for 2 weeks AND Clindamycin 600-1200 mg IV bid to qid for 2 weeks
  • Note (1): Re-injection should be considered if the infection does not improve beyond 48 hours of the first injection. Re-injection significantly increases the risk of retinal toxicity.
  • Note (2): In addition to intravitreal and systemic antibiotic therapy, vitrectomy is usually necessary
  • 4.3 Post-operative endophthalmitis
  • 4.3.1 Empiric antimicrobial therapy
  • Preferred regimen: Vancomycin 1 mg per 0.1 mL normal saline intravitreal injection, single dose AND Ceftazidime 2.25 mg per 0.1 mL normal saline intravitreal injection, single dose
  • Note (1): In addition to intravitreal antibiotic therapy, vitrectomy is necessary
  • Note (2): If there is no improvement in 48 h, a repeat intravitreal injection may be administered
  • Note (3): Late post-operative endophthalmitis is often caused by Propionibacterium acnes (several years post-op)
  • 4.3.2 Pathogen-directed antimicrobial therapy
  • 4.3.2.1 Gram-positive bacteria
  • Preferred regimen: Vancomycin 1 mg per 0.1 mL normal saline intravitreal injection, single dose
  • 4.3.2.2 Gram-negative bacteria
  • Preferred regimen: Amikacin 0.4 mg per 0.1 mL normal saline intravitreal injection, single dose
  • Note: Intravitreal amikacin is associated with the development of retinal microvasculitis
  • 4.4 Post-traumatic endophthalmitis
  • 4.4.1 Empiric antimicrobial therapy
  • Preferred regimen: Vancomycin 1 mg per 0.1 mL normal saline intravitreal injection, single dose AND Ceftazidime 2.25 mg per 0.1 mL normal saline intravitreal injection, single dose AND Amphotericin B 5-10 microgram in 0.1 mL in normal saline intravitreal injection, single dose
  • Note (1): Removal of foreign bodies and debridement of necrotic tissue is necessary
  • Note (2): In addition to antimicrobial therapy, vitrectomy is necessary
  • Note (3): Systemic broad spectrum antibiotics are recommended in post-traumatic endophthalmitis

External links

References

  1. 1.0 1.1 1.2 1.3 1.4 Durand ML (2013). "Endophthalmitis". Clin Microbiol Infect. 19 (3): 227–34. doi:10.1111/1469-0691.12118. PMC 3638360. PMID 23438028.
  2. 2.0 2.1 2.2 2.3 2.4 Kernt M, Kampik A (2010). "Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives". Clin Ophthalmol. 4: 121–35. PMC 2850824. PMID 20390032.
  3. Keay L, Gower EW, Cassard SD, Tielsch JM, Schein OD (2012). "Postcataract surgery endophthalmitis in the United States: analysis of the complete 2003 to 2004 Medicare database of cataract surgeries". Ophthalmology. 119 (5): 914–22. doi:10.1016/j.ophtha.2011.11.023. PMC 3343208. PMID 22297029.
  4. Essex RW, Yi Q, Charles PG, Allen PJ (2004). "Post-traumatic endophthalmitis". Ophthalmology. 111 (11): 2015–22. doi:10.1016/j.ophtha.2003.09.041. PMID 15522366.
  5. 5.0 5.1 Wong JS, Chan TK, Lee HM, Chee SP (2000). "Endogenous bacterial endophthalmitis: an east Asian experience and a reappraisal of a severe ocular affliction". Ophthalmology. 107 (8): 1483–91. PMID 10919895.
  6. Aaberg TM, Flynn HW, Schiffman J, Newton J (1998). "Nosocomial acute-onset postoperative endophthalmitis survey. A 10-year review of incidence and outcomes". Ophthalmology. 105 (6): 1004–10. doi:10.1016/S0161-6420(98)96000-6. PMID 9627649.
  7. Seo SW, Chung IY, Kim E, Park JM (2008). "A case of postoperative Sphingomonas paucimobilis endophthalmitis after cataract extraction". Korean J Ophthalmol. 22 (1): 63–5. doi:10.3341/kjo.2008.22.1.63. PMC 2629956. PMID 18323709.
  8. Jaru-Ampornpan P, Agarwal A, Midha NK, Kim SJ (2011). "Traumatic Endophthalmitis due to Cellulosimicrobium cellulans". Case Rep Ophthalmol Med. 2011: 469607. doi:10.1155/2011/469607. PMC 3350247. PMID 22606461.

Template:WH Template:WS